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‘For the first time ever we know that an HIV vaccine is 
possible.’
That’s what several excited top South Africa HIV/AIDS 
researchers thought following the surprise findings in 
September’s 16 000-person trial in Thailand (the much-
maligned RV 144 trial), which claimed a 31% reduction in 
infection risk among participants.
Professor Glenda Gray, head of the perinatal HIV Research 
Unit at Witwatersrand University, said the efficacy of the 
combination prime-boost vaccine paved the way for future 
designs – ‘it’s exciting 
because it means that a 
vaccine is attainable’.
She and fellow researchers 
like Professor Salim 
Abdool Karim, Director 
of the Centre for the AIDS 
Programme of Research of 
South Africa (CAPRISA), 
saw the initial results as a 
boost for sagging morale 
after so many failed trials. 
Confessed a rejuvenated 
Gray: ‘I’ve devoted my life 
to HIV vaccines since the 
early to mid 2000s – I was 
starting to wonder if I’d 
made the right choice’.
Karim said that after the 
scepticism that followed the 
failed Merck vaccine trials, 
‘this is big scientific news’, 
while Gray affirmed that 
‘this is huge’. ‘Researchers 
were becoming despondent 
about ever making a vaccine 
and were starting to become 
disinterested. Basically this 
means that a vaccine is 
possible in our lifetime.’
Then the storm broke 
around the alleged selective 
leaking of only part of the 
results by the US Military 
HIV Research Program. 
They, together with the 
Thai government, managed 
and conducted the trial, 
originally aimed at 50% 
efficacy for impact in the relatively low HIV incidence country.
An Izindaba search that included Science Magazine, The 
Wall Street Journal, The New York Times and the United Press 
International press agency, reveals that the excitement around 
the selective 24 September data release was based on a 
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‘modified intent to treat analysis’ (which prevents bias from the 
selective exclusion of trial participants from the analysis), and 
excluded the secondary ‘per protocol’ analysis.
The former includes everyone who enrolled in the study, 
regardless of whether they ended up getting the full course 
of the vaccine while the latter adheres strictly to how the trial 
was designed by only including those study participants who 
got the full regimen of the vaccine shots at the right time. The 
‘per protocol’ analysis, usually used as a supportive analysis 
to corroborate to the more stringent ‘intent to treat’ analysis, 
showed that the supposed effectiveness was only 26.2% – and 
thus not statistically significant.
This news, breaking several weeks after the two South 
African scientists were approached for comment by Izindaba, 
ignited a volcanic stream of scientific calls for laying out all 
possible data at the conclusion of trials to enable differences to 
be properly analysed.
Dr Anthony S Fauci, Director of the National Institute of 
Health which financed the trial, agreed that different analyses 
of the data could show a weaker effect but insisted that the 
one released on 24 September was ‘the gold standard’. He said 
putting several biostatistical analyses in a news release ‘would 
have confused everybody’, while suggesting that researchers 
were engaging in a cover-up was ‘absurd’.
‘They couldn’t be that stupid; they were already planning to 
give confidential briefings to experts and publish everything in 
a journal before heading to Paris, where the results would be 
presented to the world,’ he said.
However, Fauci admitted that the army’s decision to brief 
other players in the field before the 20 October Paris conference 
backfired. Statistical calculations around the ‘intent to treat’ 
analysis reportedly showed there was a 3.9% probability of the 
study results being a fluke – but for the ‘per protocol’ analysis 
this leapt to 16%. In drug and vaccine trials, anything above 
a 5% probability of a chance result is deemed statistically 
unacceptable.
Sleuths closing in on protection mechanism
Karim, whose best HIV microbicide gel trial results so far 
(PRO2000) fell just short of being statistically significant, 
believes the important thing – if moderate efficacy of the 
Thai vaccine is proven – would be that it may  be possible to 
identify what led to protection.
 ‘It’s not about getting this vaccine in a clinic anytime soon 
– we’d need to better understand what cellular and humoral 
responses were engendered. In other words, did those in the 
vaccine arm who became infected have poorer responses to 
the vaccine than those who didn’t become infected? That will 
give us clues as to what might have been responsible for the 
protection. If we can find that, it will be a major step forward 
in the field.’
Gray doubts that the Thai vaccine results will be taken 
forward in that country, where HIV incidence stands at around 
1%, in stark contrast to South Africa, where HIV incidence is 
closer to 6%. 
 ‘Thirty-one per cent doesn’t give it much value there, but in 
heavily burdened countries like ours you’d have to vaccinate 
far fewer people to get the benefit, so it would do a lot of 
good,’ Gray explained. More than five million South Africans 
are HIV positive.
Both experts cautioned that the vaccine was ‘no panacea’, 
adding that doubts existed about whether the vaccine will be 
used for anything more than further study, about how much 
was still left, and about who will be actively producing it at 
present.
Gray believes that ‘because we’ve come a long way from 
the old canary pox vaccine (which the Thai used), the question 
is should we use this or the new generation of pox vectors 
(upon which the best South African Vaccine Initiative trials are 
based)?’
Huge boost for SA pox vector research
The dramatic and at first seemingly serendipitous Thai findings 
would have thrown the pox vector research field (in which 
South Africa is a global leader), wide open.
The Vaxgen boost (monomeric gp 120) and the Aventis 
Pasteur (live replicating canary pox vector) in the Thai vaccine 
was rubbished by a prominent group of researchers in Science 
Journal in January 2004.1 They argued that Vaxgen had already 
been tested and showed no protection whatsoever while Alvac 
was tested and found to be ‘not very immunogenic’.
Writing in the ‘Policy Forum’ section of the respected journal, 
they doubted whether ‘these immunogens have any prospect 
of stimulating immune responses anywhere near adequate’, 
pointing to the cancellation of a similar phase III trial in 2003. 
The cancelled trial was to have been conducted in the USA by 
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the HIV Vaccine Trials Network (HVTN), the world’s largest 
consortium of AIDS vaccine scientists and clinicians.
Questioning the scale and cost of the Thai trial (more than 
R650 million), they said the overall approval process lacked 
input from independent immunologists and virologists who 
could have judged whether it was scientifically ‘meritorious’.
They argued that with two large phase III trials of 
immunogens that ‘all too predictably’ had already failed to 
generate protective immunity, the price of repetitive failure 
could be ‘crucial erosion of confidence by the public and 
politicians in scientific capability of developing an effective 
AIDS vaccine collectively’.
Stumbling around the edge of making history
Said Karim: ‘One of the things about vaccines (generally) 
that we seem to forget is that with most of those we have, we 
actually don’t know how they work. Many were developed 
when we couldn’t even grow those organisms or had no idea 
what immunity was required to be protective. Many were 
developed on serendipity, like the smallpox vaccine or the 
hepatitis B vaccine…we only understood them much later.’
He added: ‘So the one lesson in all this is that in vaccines, 
what we don’t know is a lot more than what we know.’
With circumcision trials for HIV prevention showing similar 
efficacy in South Africa, the Thai finding held the potential to 
become incrementally and collectively highly significant to 
containing the pandemic locally.
South Africa’s Medical Research Council president, Anthony 
Mbewu, recently said the eventual development of an HIV 
vaccine would rank among the ‘greatest achievements of 
mankind in the 21st century’.
Elise Levendal, chairperson of the South African AIDS 
Vaccine Initiative (SAAVI), emphasised that without Thailand’s 
excellent community involvement, the trial would not have 
been possible. ‘It meant a massive and dedicated community 
involvement strategy by the Thai people, NGOs and the 
sponsors. The staff of 47 health centres and eight clinical trial 
sites engaged their communities in a strategy that resulted in 
tremendous building of trust and respect…that we can learn 
from.’
While initially ‘elated’ at the results, she said they were 
no replacement for other prevention methods and that a 
vaccine would ‘always be part of a comprehensive approach’. 
Karim said one surprise factor of the results was that those 
developing the trial strategy thought they had a higher 
likelihood of reducing viral load than preventing HIV – and 
the exact opposite seemed to have happened. 
He believes much of the controversy surrounding the Thai 
trial was being driven by those who previously attacked 
the trial, ‘finding weaknesses and exploiting them’. It was 
‘important to remember’ that the secondary ‘per protocol’ 
analysis was not statistically significant because its sample size 
was smaller.
Like the discovery of penicillin, many of history’s scientific 
breakthroughs have come when researchers, tinkering on the 
edge of what is known, stumbled fortuitously into brand-new 
territory.
Chris Bateman
1.    Burton D, Desrosiers R, Doms R, Feinberg M, et al. Science  2004; 303: 316.
He added: ‘So the one lesson in all this is 
that in vaccines, what we don’t know is a 
lot more than what we know.’
November 2009, Vol. 99, No. 11  SAMJ
